N/A
N=22
QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)
Atrial Arrhythmia · QT Interval, Variation in · Arrhythmias, Cardiac
Bottom Line
View on ClinicalTrials.gov: NCT05488470 ↗Enrolled (actual)
22
Serious AEs
9.5%
Results posted
May 2025
Primary outcome: Primary: QT Intervals During Antiarrhythmic Loading Hospitalization — 21.8 milliseconds
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- LINQ/LINQ II (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Primary completion
- Jun 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY QT Intervals During Antiarrhythmic Loading Hospitalization |
21.8 | — |
Summary
The LINQ QT Study is a prospective, non-randomized, multi-center, observational, post-market clinical study investigating QT interval changes due to antiarrhythmic drug loading.
Eligibility Criteria
Inclusion Criteria
- Patients implanted with LINQ/LINQII prior to the study enrollment (no more than 50% patients implanted with LINQII), but no greater than 2.5 years for LINQ or 3.5 years for LINQII, or patients who are indicated to receive a LINQ/LINQII implant at least 7 days prior to antiarrhythmic drug loading
- Patients who are scheduled to receive antiarrhythmic drug loading
- Age 18-80
- Patient is willing and able to comply with the protocol, including follow-up visits, and performing Holter recordings and patient activation transmissions
Exclusion Criteria
- Patients who have a contraindication to long-term antiarrhythmic therapy
- Patients not suitable for long-term antiarrhythmic therapy
- Patients with a previous, existing cardiac implantation (i.e., cardiac pacemaker or cardiac resynchronization requiring > 40% pacing, implantable cardioverter defibrillator (ICDs))
- Patients with permanent and persistent AF
- Co-enrollment in another study or planning to participate in a concurrent device study during the course of this clinical study that could confound the results
Data sourced from ClinicalTrials.gov (NCT05488470). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.